No. 1 Flonase to face strong competition
The allergy space will continue to heat up significantly in 2017 as marketers pollinate the airwaves with advertisements promoting their latest brand introductions. GSK Consumer Healthcare will have its hands full defending the Flonase franchise, now the No. 1 allergy remedy on the market. Not only is there another nasal corticosteroid on the market — McNeil Consumer’s Rhinocort launched earlier this year — but Flonase faces increasing private-label and brand competition.
(To view the full ECRM Report, click here.)
Bayer recently brought ClariSpray to market, which features a fluticasone propionate active, trading on its Claritin heritage and adding yet another nasal corticosteroid to the mix.
But GSK Consumer Healthcare already has a Flonase line extension in the works. The Food and Drug Administration earlier this year approved Flonase Sensimist Allergy Relief (fluticasone furoate, 27.5 mcg spray), previously available as prescription-only Veramyst, as an over-the-counter treatment for symptoms associated with seasonal and perennial allergies. Flonase Sensimist will be available OTC in early 2017.